This is a StreetInsider.com Premium Only Page

RedHill Biopharma (RDHL) – Press Releases

Apr 8, 2024 09:23 AM RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 2, 2024 07:00 AM RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Mar 11, 2024 07:00 AM RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Mar 5, 2024 07:00 AM RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Feb 20, 2024 07:00 AM RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Jan 26, 2024 12:46 PM RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Jan 25, 2024 09:05 AM RedHill Biopharma Announces $8 Million Registered Direct Offering

Jan 25, 2024 06:00 AM RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

Dec 20, 2023 08:45 AM RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Dec 12, 2023 07:00 AM RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 4, 2023 07:00 AM RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

Nov 27, 2023 07:00 AM RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Nov 14, 2023 08:00 AM RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

Oct 3, 2023 07:00 AM RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

Sep 22, 2023 04:15 PM RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Sep 18, 2023 07:00 AM RedHill Announces FDA sNDA Approval for Talicia®

Sep 5, 2023 07:00 AM RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

Aug 18, 2023 07:52 AM This Week in Health News: 11 Stories You Need to See

Aug 17, 2023 07:00 AM RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

Aug 1, 2023 07:00 AM RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

Jul 31, 2023 07:00 AM RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

Jul 25, 2023 03:58 PM RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise

Jul 21, 2023 09:33 AM RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds

Jul 21, 2023 07:00 AM RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development

Jul 6, 2023 08:00 AM Phil and RedHill Biopharma Partner to Increase Access to Talicia®

Jun 12, 2023 08:00 AM RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

May 22, 2023 07:00 AM RedHill Provides R&D Update

May 15, 2023 06:17 PM RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

May 9, 2023 07:00 AM RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

May 1, 2023 07:00 AM RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

Apr 28, 2023 07:00 AM RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights

Apr 11, 2023 07:00 AM RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 3, 2023 01:26 PM RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering

Mar 30, 2023 08:00 AM RedHill Biopharma Announces $6 Million Registered Direct Offering

Mar 21, 2023 07:00 AM RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders

Mar 16, 2023 06:15 PM RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Mar 8, 2023 07:05 PM RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor

Feb 28, 2023 08:01 AM RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development

Feb 28, 2023 07:00 AM RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program

Feb 16, 2023 08:01 AM RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan

Feb 16, 2023 08:00 AM RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support

Feb 15, 2023 07:00 AM RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

Feb 6, 2023 07:00 AM RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®

Jan 26, 2023 07:00 AM RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

Jan 3, 2023 07:00 AM RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19

Dec 7, 2022 09:45 AM Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)

Dec 6, 2022 01:36 PM RedHill Biopharma Closes $8.0 Million Underwritten Public Offering

Dec 5, 2022 07:00 AM RedHill's Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension

Dec 2, 2022 09:00 AM RedHill Biopharma Prices $8.0 Million Underwritten Public Offering

Dec 1, 2022 04:01 PM RedHill Biopharma Announces Proposed Public Offering